Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/0284186X.2016.1230275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Sleeping Giant: Late HBV Reactivation After Rituximab-Based Chemotherapy Despite Correct Prophylaxis.
Int Med Case Rep J
December 2024
Clinical Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
Hepatitis B virus (HBV) reactivation is a recognized complication of long-term immunosuppressive or cytotoxic therapy, typically occurring during immunosuppression or within a few months after treatment. To mitigate this risk, hepatological societies recommend the use of nucleos(t)ide analogues (NA) for HBV reactivation prophylaxis, along with post-treatment monitoring; though, these recommendations are not universally consistent across different guidelines. We present a case of late HBV reactivation in a 76-year-old male with occult HBV infection who received rituximab-based therapy for chronic lymphocytic leukemia.
View Article and Find Full Text PDFThe Course of COVID-19 Infection in Patients With Chronic Hepatitis Delta.
J Viral Hepat
January 2025
Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.
In coronavirus disease 2019 (COVID-19), older age and co-morbidities are associated with mortality. Among liver disease aetiologies alcoholic liver disease was associated with mortality. Chronic hepatitis delta (CHD) had not been studied.
View Article and Find Full Text PDFCase report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis.
Front Oncol
December 2024
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated both efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients infected with hepatitis B virus (HBV). However, its applicability in individuals with liver cirrhosis remains largely unexplored due to the potential for unpredictable complications. Here, we report three cases (P1, P2, and P3) of relapsed/refractory DLBCL with HBV-related cirrhosis treated with CAR-T cell infusion.
View Article and Find Full Text PDFCytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib.
J Oncol Pharm Pract
December 2024
Michigan Medicine, Clinical Pharmacist Specialist, Inpatient Hematology, University of Michigan, Ann Arbor, MI, USA.
Introduction: Mutated rearranged during transfection (RET) kinase is found in approximately 1-2% non-small-cell lung cancer (NSCLC) patients. These patients are typically younger, non-smokers, and have non-squamous histology. Pralsetinib is a novel RET inhibitor that showed promising efficacy and tolerability in the ARROW trial.
View Article and Find Full Text PDFHepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas.
Cancers (Basel)
November 2024
School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Article Synopsis
- Everolimus, a drug for treating certain cancers, poses a risk of hepatitis B virus (HBV) reactivation and hepatitis, particularly in patients with current or past HBV infection.
- A study involving 377 patients on everolimus found that 28.75% of those with active HBV (HBsAg-positive) and 17.85% of those without (HBsAg-negative) developed hepatitis, with higher risks associated with specific treatments and lack of prophylaxis.
- The research emphasizes the need for HBV screening and careful liver function monitoring for patients receiving everolimus, especially in regions where HBV is common.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!